Forbes April 16, 2024
William A. Haseltine

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged by disease, injured by trauma, or worn by time to normal function. I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal.

In this subseries, we focus specifically on gene therapies. We explore the current treatments and examine the advances poised to transform healthcare. Each article in this collection delves into a different aspect of gene therapy’s role within the larger narrative of Regenerative Medicine. This piece begins a miniseries on gene therapy vectors and their significance.

Gene therapy...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Oh, Canada: U.S. Patients Don't Want Your Health Policies
Steep Ozempic, Wegovy prices face fresh scrutiny from officials
Walgreens’ Next Frontier: Complex Conditions & Cell And Gene Therapy
Aviv Regev: The Revolution in Digital Biology
Global Inequities In Access To Drugs Costs Millions Of Lives Each Year

Share This Article